RudaCure, une entreprise spécialisée dans le développement de traitements pour les maladies oculaires et la douleur chronique, a été sélectionnée comme 'Baby Unicorn' representing Korea in the bio sector, recognized for the innovantness and potentiel de croissance of its technology. With this selection, RudaCure a réalisé a double crown as a nationally representative prometteur entreprise startup following its 'BIG3' program selection in 2020.
RudaCure Inc. (PDG Yongho Kim) a annoncé that it a été définitivement sélectionnée pour the '2024 Global Unicorn Project' supported by the Ministère de SMEs and Startups, enabling l'entreprise to receive full-scale growth support as a 'Baby Unicorn' company for one year.
The 'Global Unicorn Project' is a national representative startup support policy to revitalize Korea's startup écosystème and nurture globally compétitif unicorn companies. Selected companies receive specialized support for marché mondial entry, strategic attraction d'investissements, and sustainable growth capabilities.
RudaCure a été reconnue pour the innovant potential of its proprietary TRPV1 (Transient Receptor Potential Vanilloid 1) canal ionique modulation-based développement de médicaments technology, along with its achievements in attracting Series A/B investissements totaling over KRW 16 billion and transfert de technologie contrats exceeding KRW 70 billion.
le PDG Yongho Kim a déclaré : "Being selected for the Global Unicorn Project is meaningful recognition of RudaCure's potentiel de croissance and innovant technology. We will leverage this opportunity to accelerate our IPO preparations and strengthen our marché mondial position."